EMEA-002978-PIP01-21

Table of contents

Key facts

Invented name
Enhertu
Active substance
trastuzumab deruxtecan
Therapeutic area
Oncology
Decision number
P/0275/2021
PIP number
EMEA-002978-PIP01-21
Pharmaceutical form(s)
All pharmaceutical forms
Condition(s) / indication(s)
Treatment of lung cancer
Route(s) of administration
All routes of administration
Contact for public enquiries
Daiichi Sankyo Europe GmbH
E-mail: service@daiichi-sankyo.eu
Tel.: +49 8978080
Decision type
W: decision granting a waiver in all age groups for all conditions or indications

Decision

Related content

How useful was this page?

Add your rating